Note
Simulated ‘in-use’ and ‘mis-use’ aspects of the delivery of terbutaline sulphate from Bricanyl TurbohalerTM dry powder inhalers

https://doi.org/10.1016/0378-5173(94)00388-LGet rights and content

Abstract

Using three different environmental conditions, patient ‘use’ of Bricanyl TurbohalersTM has been simulated over a 9 week period during which approx. 90% of the nominal number of doses were discharged. Qualitative assessment indicated dose metering efficiency remained within 15% of initial estimates. Drug dose obtained by drawing air at 60 1 min−1 through the devices also remained constant, whereas at 28 1 min-1 the emission was reduced to half the initial value obtained over the use period. A fall in fine particle fraction (0.4–5.8 μm) from 20 to 7% over use at 30°C/72% RH and to zero over use at 5°C was observed. Patient ‘mis-use’ involving incorrect loading orientation showed a small reduction in dose emission from a mean of 414 μg to 382 μg. Exhaling into the TurbohalerTM perturbed the fine particle fraction for the three subsequent shots although dose emission was restored after one shot.

References (8)

  • B.J. Meakin et al.

    Drug delivery characteristics of Bricanyl TurbohalerTM dry powder inhalers

    Int. J. Pharm.

    (1995)
  • Astra

    Statement on Turbohaler

    Pharm. J.

    (1991)
  • P.H. Brown et al.

    Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists

    Eur. Resp. J.

    (1992)
  • J. Duncan et al.

    Clinical assessment of a new multidose nonpressurised metered-dose inhaler

    Drug. Invest.

    (1990)
There are more references available in the full text version of this article.

Cited by (0)

View full text